Kalray Showcases Leading Solutions for High-performance Computing and Unstructured Data at Dell Technologies World 2023
27.4.2023 18:45:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL) , a leading provider of hardware and software technologies and solutions for high-performance data-centric computing markets, from Cloud to Edge, is pleased to announce its presence at Dell Technologies World as a Dell ETC Partner, from May 22 to 25, 2023, in Las Vegas.
Dell Technologies World (DTW) is a major annual event that brings together industry leaders, experts, and customers to discuss the latest trends and innovations in technology. The event covers a wide range of topics and attracts thousands of attendees from around the world.
Kalray will be exhibiting at DTW as a Dell Technologies ETC Partner. The ETC program is a Dell Technologies partnership program delivering all-in-one solutions, combining selected ETC partner solutions with Dell Technologies servers, storage, and networking, to create an industry-leading value proposition.
With its solutions, Kalray addresses the challenges of data-intensive workloads for use cases such as Artificial Intelligence, Machine Learning, High-Performance Computing, IoT processing, and unstructured data. Primary verticals are Life Sciences, Manufacturing, Higher Education, and Finance. All have requirements to process and manage unstructured data in a fast and efficient way, wherever the data resides.
“This is a great opportunity for Kalray to demonstrate our unique portfolio for HPC and Unstructured Data Solutions, to enterprise customers," says Kalray CEO, Éric Baissus. “The exhibition booth and joint presentation activities at Dell Technologies World is part of our strategy to accelerate our go-to-market and strengthen our offering with Dell Technologies."
pixstor™ with ngenea® , combined with Dell Technologies solutions, provides customers an all-in-one, easy-to-use solution that meets the requirements of demanding storage workloads. pixstor’s™ “Tier-Zero” scratch storage enables customers to dramatically increase storage performance, while ngenea® vastly improves efficiency by consolidating storage environments such as Dell PowerScale and ECS, simplifying data management workflows.
Associated with Kalray’s DPU-based cards , Kalray provides a unique hardware and software storage offering.
At Dell Technologies World, attendees can learn more about Kalray’s award-winning solutions at booth #1729. The Kalray team will be showcasing several live product demos:
- pixstor™ Search finds data across an entire data namespace, without opening a single file. Bring users closer to their data and reducing time spent locating files.
- Discover ngenea®2 self-service for the world of HSM (Hierarchical storage Management). Watch live as ngenea®2 controls site-to-site replication and cloud bursting, without needing administrative privileges or cloud expertise.
- Global Sync- Distributed workflow challenges call for a distributed workflow solution. Keep your global footprint in sync and up to date, even with hundreds of thousands of changes per hour.
- Kalray will be also introducing a high-performance NVMe-based Tier-0 storage solution based on its DPU (Data Processing Unit) acceleration cards and Dell Technologies server. Designed for data-intensive workloads and applications, this solution offers unique benefits in term of performance per watt and performance per dollar.
Register your interest in our product showcase or book a meeting with our technical experts here:
https://www.kalrayinc.com/dtw-2023
About KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from Cloud to Edge. Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures.
Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Sciences, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005601/en/
Contact information
INVESTOR CONTACTS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone: + 33 4 76 18 90 71
ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone: + 33 1 53 67 36 72
PRESS CONTACTS
Sylvie DAM
communication@kalrayinc.com
Phone: +33 4 76 18 90 71
ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone: +33 4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom